Boston Scientific said its fourth-quarter net income rose 12% amid robust demand for its stents, catheters and other cardiology devices. The Marlborough, Mass., medical-device maker posted ...

he directed marketing for key products such as drug-eluting stents and echocardiograms at Boston Scientific's cardiovascular division. He served as the representative of Philips Korea from 2018 to ...

Boston Scientific has recently reported the results of the Optical Coherence Tomography Drug Eluting Stent Investigation (OCTDESI)trial; part of the JACTAX stent program. [30] The JACTAX stent con ...

Germany presented an increased emphasis on advanced stents, with 1.3 million drug-eluting stents deployed ... imaging catheters across Europe. Boston Scientific introduced 3 advanced balloon ...

Boston Scientific BSX is slated to report ... However, this might have been offset by the ongoing price pressure on drug-eluting stents. The consensus estimate for Interventional Cardiology ...

Boston Scientific BSX is slated to report fourth-quarter fiscal 2024 results on Feb. 5 before market open. See the Zacks Earnings Calendar to stay ahead of market-making news. For fourth-quarter ...

In 2012, J&J agreed to pay US $181 million to 26 states in order to settle these claims – though another lawsuit related to the drug ... Boston Scientific involving patents covering heart stent ...

Drug-eluting balloons (DEBs) represent a significant advancement in the field of interventional cardiology, offering an innovative approach to treat coronary artery disease. Unlike traditional stents ...

Boston Scientific Announces Acquisition Agreement for Bolt Medical ... approval to initiate the company’s ELITE-BTK pivotal trial of Magnitude, its next-generation drug-eluting bioresorbable scaffold ...

Medical device maker Boston Scientific forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.